Arcutis Biotherapeutics, Inc. ARQT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.07M-34.7% | $43.22M-39.9% | $47.43M-65.0% | $73.05M-13.9% | $53.72M-71.8% | ||
| $189.24M+30.5% | $178.08M+13.7% | $143.95M-26.4% | $118.08M-57.5% | $144.98M-32.2% | ||
| $308K-50.1% | $308K-50.1% | $308K-50.1% | $308K-50.1% | $617K0.0% | ||
| $144.38M+69.0% | $146.23M+100% | $115.12M+91.5% | $106.69M+146% | $85.42M+130% | ||
| $37.39M+125% | $22.63M+55.8% | $22.42M+60.0% | $16.32M+17.6% | $16.61M+25.4% | ||
| $16.38M+117% | $5.05M+17.4% | $6.12M+49.6% | $6.72M+10.3% | $7.56M-7.8% | ||
| $6.33M+709% | $5.03M+762% | $4.73M+165% | $1.74M-11.9% | $783K-66.0% | ||
| $14.68M+77.5% | $12.55M+30.2% | $11.58M+42.1% | $7.87M+35.2% | $8.27M+202% | ||
| $31.98M+39.4% | $21.08M+7.2% | $20.31M+10.3% | $18.64M+30.8% | $22.94M+74.1% | ||
| $140.37M— | $138.4M— | —— | —— | —— | ||
| $438.06M+35.3% | $411.23M+22.5% | $349.22M-17.6% | $332.78M-23.4% | $323.67M-30.8% | ||
| $1.04M-30.5% | $1.04M+0.2% | $1.22M+2.4% | $1.39M+3.5% | $1.5M+9.3% | ||
| $4.36M+137% | $4.47M+129% | $4.57M+122% | $1.73M-20.1% | $1.84M-18.6% | ||
| $14.25M-13.6% | $14.81M+56.3% | $15.38M+57.0% | $15.94M+163% | $16.5M+164% | ||
| $2.3M+285% | $1.42M+138% | $596K0.0% | $596K+0.2% | $596K0.0% | ||
| $48.87M— | $39.68M— | —— | —— | —— | ||
| $460M+33.7% | $432.97M+24.1% | $370.98M-15.2% | $352.43M-20.8% | $344.11M-28.1% | ||
| $18.3M-25.4% | $12.53M-11.9% | $5.8M-70.0% | $15.08M+89.9% | $24.53M+89.1% | ||
| $10.32M+12.7% | $20.53M-69.3% | $18.3M+17.1% | $12.32M+23.1% | $9.16M+22.5% | ||
| $7.95M— | $1M— | $1M-99.0% | $1M— | —— | ||
| $163.2M+79.1% | $129.84M+60.3% | $99.77M-42.1% | $103.94M+102% | $91.13M+92.6% | ||
| $101.47M-5.7% | $107.96M+0.7% | $107.5M+2.3% | $107.05M-47.5% | $107.62M-46.9% | ||
| $5.25M+124% | $5.27M+106% | $5.28M+90.3% | $2.11M-29.0% | $2.34M-26.4% | ||
| $431K+19.7% | $431K-24.4% | $360K-14.3% | $360K+85.6% | $360K+17.6% | ||
| $270.36M+34.2% | $243.49M+27.3% | $212.9M-24.2% | $213.46M-17.4% | $201.45M-20.6% | ||
| 300M0.0% | 300M+2,499,900% | 300M0.0% | 300M0.0% | 300M0.0% | ||
| $1.34B+3.9% | $1.33B+3.8% | $1.31B+3.7% | $1.3B+3.6% | $1.29B+3.8% | ||
| -$1.15B-0.2% | -$1.14B-1.4% | -$1.16B-4.0% | -$1.16B-8.7% | -$1.15B-12.8% | ||
| -$514K-267% | -$44K-529% | -$62K-112% | -$35K+88.1% | -$140K-5.3% | ||
| $189.65M+32.9% | $189.48M+20.3% | $158.07M+0.9% | $138.97M-25.5% | $142.66M-36.6% | ||
| $460M+33.7% | $432.97M+24.1% | $370.98M-15.2% | $352.43M-20.8% | $344.11M-28.1% | ||
| $140.44M-3.0% | $138.28M-11.5% | $143.79M-26.3% | $118M-57.6% | $144.8M-32.3% | ||
| $140.44M— | $138.28M— | —— | —— | —— | ||
| $189.24M+30.5% | $178.08M+13.7% | $143.95M-26.4% | $118.08M-57.5% | $144.98M-32.2% | ||
| $189.24M+30.5% | $178.08M+13.7% | $143.95M-26.4% | $118.08M-57.5% | $144.98M-32.2% | ||
| $14.68M+77.5% | $12.55M+30.2% | $11.58M+42.1% | $7.87M+35.2% | $8.27M+202% | ||
| $49.03M— | $39.68M— | —— | —— | —— | ||
| $2.3M+285% | $1.42M+138% | $596K0.0% | $596K+0.2% | $596K0.0% | ||
| $189.48M+30.9% | $177.96M+13.9% | $143.79M-26.3% | $118M-57.6% | $144.8M-32.3% | ||
| $4.36M+137% | $4.47M+129% | $4.57M+122% | $1.73M-20.1% | $1.84M-18.6% | ||
| $14.25M-13.6% | $14.81M+56.3% | $15.38M+57.0% | $15.94M+163% | $16.5M+164% | ||
| $4.36M+137% | $4.47M+129% | $4.57M+122% | $1.73M-20.1% | $1.84M-18.6% | ||
| $2.3M+285% | $1.42M+138% | $596K0.0% | $596K+0.2% | $596K0.0% | ||
| $4.36M+137% | $4.47M+129% | $4.57M+122% | $1.73M-20.1% | $1.84M-18.6% | ||
| $2.3M+285% | $1.42M+138% | $596K0.0% | $596K+0.2% | $596K0.0% | ||
| $10.32M+12.7% | $20.53M-1.0% | $18.3M+17.1% | $12.32M+23.1% | $9.16M+22.5% | ||
| $136.96M+108% | $116.31M+74.1% | $92.98M+76.1% | $87.85M+106% | $65.76M+95.8% | ||
| $136.96M+108% | $116.31M+74.1% | $92.98M+76.1% | $87.85M+106% | $65.76M+95.8% | ||
| $10.32M+12.7% | $20.53M-1.0% | $18.3M+17.1% | $12.32M+23.1% | $9.16M+22.5% | ||
| $107M0.0% | —— | $107M-50.0% | $107M-50.0% | $107M-50.0% | ||
| $798K-24.7% | $865K-22.8% | $932K-60.5% | $998K-61.1% | $1.06M-62.4% | ||
| $114.67M+3.5% | $114.52M+3.6% | $113.77M-45.3% | $110.16M-46.9% | $110.8M-46.4% | ||
| $100M0.0% | $100M0.0% | $100M-50.0% | $100M-50.0% | $100M-50.0% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 310M— | —— | —— | —— | —— | ||
| 125M+5.0% | 123.3M+4.7% | 120.3M+2.8% | 119.8M+2.8% | 119.1M+3.1% | ||
| $90.57M+74.1% | $127.95M+197% | $69.6M+195% | $40.75M+60.9% | $52.02M+81.1% | ||
| 10M0.0% | —— | 10M0.0% | 10M0.0% | 10M0.0% | ||
| 0— | —— | 0— | 0— | 0— | ||
| $12K0.0% | $12K0.0% | $12K0.0% | $12K0.0% | $12K0.0% | ||
| 3.1M+41.2% | —— | 2.9M+38.7% | 2.8M+36.8% | 2.2M+13.0% | ||
| 7.6M+9.2% | 6.4M+20.5% | 6.7M+19.4% | 6.9M+17.9% | 7M+27.2% | ||
| $13K-93.0% | $134K-58.0% | $156K-75.2% | $90K+374% | $187K+648% | ||
| $251K+4,920% | $21K— | $2K+100% | $3K-98.1% | $5K-87.8% | ||
| $12.39+42.7% | $9.17+37.1% | $8.83+35.6% | $8.77+38.8% | $8.68+38.2% | ||
| $189.48M+30.9% | $177.96M+13.9% | $143.79M-26.3% | $118M-57.6% | $144.8M-32.3% | ||
| $99.53M+112% | $78.31M+104% | $61.31M+104% | $63.56M— | $47.01M— | ||
| $10M— | $0— | —— | —— | —— | ||
| $251K+4,920% | $21K— | $2K+100% | $3K-98.1% | $5K-87.8% | ||
| $13K-93.0% | $134K-58.0% | $156K-75.2% | $90K+374% | $187K+648% | ||
| $189.48M+30.9% | $177.96M+13.9% | $143.79M-26.3% | $118M-57.6% | $144.8M-32.3% | ||
| $49.03M— | $39.68M— | —— | —— | —— | ||
| $48.87M— | $39.68M— | —— | —— | —— | ||
| $140.44M— | $138.28M— | —— | —— | —— | ||
| $140.37M— | $138.4M— | —— | —— | —— | ||
| $189.24M+30.5% | $178.08M+13.7% | $143.95M-26.4% | $118.08M-57.5% | $144.98M-32.2% | ||
| $310M— | —— | —— | —— | —— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $224.3M+12.9% | $221.3M-3.2% | $191.4M-42.2% | $191.1M-47.4% | $198.7M-50.9% | ||
| $692K+2,668% | $425K— | $228K-21.9% | $74K-76.8% | $25K-99.3% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $300M0.0% | $300M0.0% | $300M0.0% | $300M0.0% | $300M0.0% | ||
| $125.04M+5.0% | $123.33M+4.7% | $120.29M+2.8% | $119.8M+2.8% | $119.14M+3.1% | ||
| $125.04M+5.0% | $123.33M+4.7% | $120.29M+2.8% | $119.8M+2.8% | $119.14M+3.1% | ||
| $9.22M+20.1% | $8.82M+20.5% | $8.43M+20.9% | $8.05M+26.2% | $7.68M+36.5% | ||
| $1M0.0% | $1M0.0% | $1M— | $1M— | $1M— | ||
| $100M0.0% | $100M0.0% | $100M-50.0% | $100M-50.0% | $100M-50.0% | ||
| —— | —— | $5.4M— | —— | —— | ||
| $107M— | —— | —— | —— | —— | ||
| $16.41M+71.6% | $17.04M+124% | $13.13M+92.2% | $11.9M+27.8% | $9.57M+58.6% | ||
| $10M0.0% | —— | $10M0.0% | $10M0.0% | $10M0.0% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $2.97M-12.2% | $2.58M-20.6% | $396K— | $0-100% | $3.38M+121% | ||
| $15.69M+127% | $9.49M+28.7% | $9.26M+3.7% | $9.96M+293% | $6.92M— | ||
| $3.09M+41.2% | —— | $2.94M+38.7% | $2.81M+36.8% | $2.19M+13.0% | ||
| $7.6M+9.2% | $6.44M+20.5% | $6.73M+19.4% | $6.92M+17.9% | $6.96M+27.2% | ||
| $12.39+42.7% | $9.17+37.1% | $8.83+35.6% | $8.77+38.8% | $8.68+38.2% | ||
| $90.57M+74.1% | $127.95M+197% | $69.6M+195% | $40.75M+60.9% | $52.02M+81.1% | ||
| $8.45+4.7% | —— | $8.33+2.1% | $8.26+3.1% | $8.07-14.1% | ||
| $47.5M+137% | —— | $33.11M+280% | $20.36M+136% | $20.02M+128% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arcutis Biotherapeutics, Inc.'s total assets?
- Arcutis Biotherapeutics, Inc. (ARQT) holds $460.0M in total assets, up 33.7% year over year.
- How much debt does Arcutis Biotherapeutics, Inc. have?
- Arcutis Biotherapeutics, Inc. carries $114.7M in total debt against $189.6M of shareholders' equity, a debt-to-equity ratio of 0.60.
- How much cash does Arcutis Biotherapeutics, Inc. have?
- Arcutis Biotherapeutics, Inc. holds $35.1M in cash and equivalents.
- Can Arcutis Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 2.68 — current assets exceed current liabilities.
- Where does Arcutis Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
